Platinum Partners Value Arbitrage Fund v. Chicago Board Options Exchange
976 N.E.2d 415
Ill. App. Ct.2012Background
- Plaintiff Platinum Partners sued CBOE, OCC, and John Doe defendants alleging Illinois securities and consumer fraud claims based on privately disclosed information about an IFN option strike-price adjustment.
- The IFN adjustment was a regulatory decision intended to account for an extraordinary dividend impacting option values.
- Plaintiff alleges insiders received the price-adjustment information before public disclosure and plaintiff bought put options relying on lack of public disclosure.
- Trial court dismissed on grounds of absolute regulatory immunity for the SROs, without leave to amend.
- On appeal, plaintiff seeks reversal and remand for merits or leave to amend; defendants argue immunity and failure to state a claim.
- The court ultimately holds that the nonpublic disclosure is not immunized by regulatory immunity and reverses the dismissal.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Is regulatory immunity applicable to the challenged disclosure? | Plaintiff argues immunity does not apply to the private disclosure. | CBOE and OCC contend disclosure was within regulatory duties. | No; immunity does not apply to private disclosure. |
| Do the Illinois anti-fraud and Consumer Fraud Act claims state a claim? | Plaintiff asserts omissions and misrepresentations via private disclosure. | Defendants argue no duty to disclose to plaintiff/public. | The claims are adequately pled. |
| Was leave to amend appropriate after immunity ruling? | Amendment could add facts and new claims. | Amendment would be futile under immunity. | The trial court should have considered amendment; in this record, leave to amend was allowed. |
| Should the complaint be dismissed without leave to amend if immunity exists? | Immunity does not bar all theories, warranting merit review. | Immunity bars private claims. | Reversal of dismissal; remand for merits under non-immunity grounds. |
Key Cases Cited
- In re NYSE Specialists Securities Litigation, 503 F.3d 89 (2d Cir. 2007) (regulatory immunity hinges on the objective function, not motive; timing/method of announcements protected)
- Weissman v. National Ass’n of Securities Dealers, Inc., 500 F.3d 1293 (11th Cir. 2007) (immunity narrowly construed; private actions limited)
- Sparta Surgical Corp. v. National Association of Securities Dealers, Inc., 159 F.3d 1209 (9th Cir. 1998) (immunity applies to regulatory power; not to all actions)
- DL Capital Group, LLC v. Nasdaq Stock Market, Inc., 409 F.3d 93 (2d Cir. 2005) (public announcements of regulatory actions protected; carving out of immunity disfavored)
- Standard Investment Chartered, Inc. v. National Ass’n of Securities Dealers, Inc., 637 F.3d 112 (2d Cir. 2011) (timing and method of announcement entitled to immunity; multiple regulatory functions)